Molecular Partners AG (MOLN)
NASDAQ: MOLN · IEX Real-Time Price · USD
7.00
-0.20 (-2.78%)
At close: Jul 2, 2024, 3:58 PM
6.87
-0.13 (-1.86%)
After-hours: Jul 2, 2024, 6:45 PM EDT
Molecular Partners AG Revenue
Molecular Partners AG had revenue of $7.64M in the twelve months ending March 31, 2024, down -64.99% year-over-year. Revenue in the quarter ending March 31, 2024 was $3.11M, a -7.17% decrease year-over-year. In the year 2023, Molecular Partners AG had annual revenue of $8.38M, a decrease of -95.89%.
Revenue (ttm)
$7.64M
Revenue Growth
-64.99%
P/S Ratio
30.39
Revenue / Employee
$45,768
Employees
167
Market Cap
232.27M USD
Revenue Chart
* The company reports in CHF currency but revenue data is shown in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 8.38M | -195.49M | -95.89% |
Dec 31, 2022 | 203.87M | 193.15M | 1,802.02% |
Dec 31, 2021 | 10.72M | 100.50K | 0.95% |
Dec 31, 2020 | 10.62M | -10.40M | -49.47% |
Dec 31, 2019 | 21.01M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Auna SA | 1.06B |
AngioDynamics | 324.01M |
Sutro Biopharma | 154.07M |
Sanara MedTech | 68.00M |
Semler Scientific | 65.88M |
Aquestive Therapeutics | 51.50M |
Utah Medical Products | 49.04M |
Nyxoah | 5.57M |
MOLN News
- 15 days ago - Molecular Partners to Present at The TD Cowen Radiopharmaceutical Innovation Summit - GlobeNewsWire
- 18 days ago - Molecular Partners Presents Positive Preclinical Data for First Switch-DARPin Candidate MP0621 at EHA 2024 - GlobeNewsWire
- 21 days ago - Molecular Partners and Orano Med Share Positive Preclinical Data of their DLL3-Targeting Radio-DARPin Therapy (RDT) Candidate MP0712 at SNMMI 2024 - GlobeNewsWire
- 4 weeks ago - Molecular Partners Presents Positive Data From Completed Phase 1 Trial Of MP0317 (FAP X CD40 DARPin) Monotherapy In Patients With Advanced Solid Tumors At ASCO 2024 - GlobeNewsWire
- 6 weeks ago - Interim Management Statement Q1 2024 of Molecular Partners: Pipeline Progressing with Two Additional Programs to Enter the Clinic in 2025, Update to MP0533 Program - GlobeNewsWire
- 2 months ago - Molecular Partners Announces Publication in Cancer Immunology Research of Preclinical Data Supporting MP0533's Proposed Mechanism of Action - GlobeNewsWire
- 2 months ago - Life Science Cares Launches in Switzerland - GlobeNewsWire
- 2 months ago - Molecular Partners Announces All Board Proposals Approved at the Annual General Meeting - GlobeNewsWire